- Conditions
- Dysmenorrhea, Pain
- Interventions
- Naproxen
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 1,869
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
- Interventions
- Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride
- Behavioral · Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 60 Years to 99 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Healthy
- Interventions
- Mycophenolate Mofetil, CellCept®
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Glioblastoma
- Interventions
- Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection
- Radiation · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more
- Conditions
- Schizophrenia
- Interventions
- TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Extreme Prematurity
- Interventions
- Epo, Control
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 24 Weeks to 27 Weeks
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more
- Conditions
- Glioblastoma Multiform (Grade IV Astrocytoma)
- Interventions
- PolyMVA
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Active tDCS, Sham tDCS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture, Closed Lower Extremity Fracture, Pelvic Fracture
- Interventions
- DuraPrep, ChloraPrep
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 24
- States / cities
- Irvine, California • Los Angeles, California • San Jose, California + 20 more
- Conditions
- Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
- Interventions
- ONCOS-102, Durvalumab, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- San Diego, California • Miami, Florida • Buffalo, New York + 3 more
- Conditions
- Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Gemcitabine, Nab-paclitaxel, L-glutamine
- Drug
- Lead sponsor
- Jun Gong, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Los Angeles, California
- Conditions
- Melanoma
- Interventions
- Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Springdale, Arkansas + 4 more
- Conditions
- Opioid-Induced Constipation
- Interventions
- Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 77
- States / cities
- Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
- Conditions
- Chronic Ankle Instability
- Interventions
- Ankle Joint Mobilization, Foot Massage, Calf Stretching
- Other
- Lead sponsor
- Joel Thompson
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Ithaca, New York • Charlotte, North Carolina
- Conditions
- Sleep Apnea Syndromes
- Interventions
- NightBalance Sleep Position Trainer (SPT), Automated Adjusting Positive Airway Pressure (APAP)
- Device
- Lead sponsor
- NightBalance
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Gainesville, Florida + 8 more
- Conditions
- Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
- Interventions
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Drug · Combination Product
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Substance Use Disorders, Pain
- Interventions
- SBIRT-PM
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • West Haven, Connecticut
- Conditions
- Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
- Interventions
- Pegylated Interferon alpha-2b, Capecitabine, 5-FU
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Nervous System Disease, Genetic Syndrome
- Interventions
- EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
- Drug
- Lead sponsor
- Quince Therapeutics S.p.A.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
- Conditions
- Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
- Interventions
- Ipilimumab, Best Supportive care (BSC)
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Miami Beach, Florida • New York, New York • Houston, Texas
- Conditions
- Wilson Disease
- Interventions
- Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60), TETA 4HCL (60-<W108)
- Drug
- Lead sponsor
- Orphalan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Docetaxel, LY2181308
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
- Conditions
- Atherosclerosis
- Interventions
- Aliskiren, Placebo
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio